ver since its discovery more than 2 decades ago, remote ischemic preconditioning (RIPC) has generated tremendous interest among scientists and clinicians alike. However, two recent large, well-conducted, randomized controlled trials (RCTs) have failed to identify any significant benefit of RIPC during cardiac surgery. A reconciliatory yet objective review of cumulative evidence with regard to cardiac surgery reveals that RIPC in preclinical studies reduced infarct size after experimental myocardial infarction (MI), which is different from cardiac surgery; improved release of biomarkers, but not hard clinical end points, in proof-of-concept clinical trials with discordant results; and failed to produce significant improvement in outcomes in meta-analyses. This difficult journey of RIPC across the valley of death underscores the importance of scientific rigor and exercise of caution in interpreting data at every step of the way until efficacy of a purported therapy is proven conclusively in large RCTs.
RIPC is a phenomenon, whereby brief episodes of ischemia in a distant vascular bed protect other organs in the body from subsequent ischemic injury. The concept that a noninvasive and simple procedure can protect organs during elective ischemic episodes has continued to generate tremendous interest among clinicians and scientists. Promising results from numerous basic studies led to many smaller clinical trials and meta-analyses, and then to two large, well-conducted RCTs. The recent results from Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery (ERICCA) and RIPHeart, however, have failed to identify any significant benefit of RIPC on hard clinical end points or surrogate markers of organ protection. 1, 2 Because hindsight is often 20/20, it is important to interpret these latest findings in light of relevant data accumulated over the past 2 decades.
Reduction in Infarct Size in Preclinical Studies
In 1993, Przyklenk et al 3 first reported reduction in infarct size after left anterior descending coronary artery occlusion in dogs that underwent prior ischemia/reperfusion in left circumflex coronary artery territory. Subsequent studies showed that brief ischemia/reperfusion episodes in remote renal, mesenteric, cerebral, aortic, and femoral vascular beds could also afford protection against subsequent MI in rats, rabbits, pigs, and mice. 4 The RIPC-induced improvements in cardiac parameters were largely due to a major reduction in infarct size. 4 Although these studies in different species nearly unanimously indicated that RIPC imparts marked benefits, some reports did question its efficacy. In a study in rabbits, Nakano et al 5 found no significant infarct-sparing effect of regional coronary ischemia/reperfusion in distant myocardial segments. More recently, Schmidt et al 6 have reported worsening of infarct size and LV function with RIPC in neonatal rabbit hearts and lack of significant protection in neonatal pig hearts in the absence of concomitant metabolic intervention. 7 In addition, a substantive amount of research effort has also been dedicated toward understanding the mechanisms of RIPC and identifying key molecules that trigger or mediate RIPC. 8 Many of these in vivo studies have established causal relationships of specific signaling pathways with protection offered by RIPC beyond reasonable doubt. The diversity of species, models, and protocols were perhaps no more than what would be inherent in any topic of investigation that involves in vivo experimentation.
Discordant Data From Proof-of-Concept Clinical Studies
The strength of preclinical evidence and the potentially negligible side effects of RIPC protocols quickly led to testing of safety and efficacy in humans. In 2000, Gunaydin et al 9 reported the first human data from a small randomized study with 4 patients who underwent RIPC in right arm with 2 cycles of 3-minute ischemia/2-minute reperfusion and 4 controls undergoing coronary artery bypass surgery (CABG). Five minutes after the release of aortic cross-clamp, lactate dehydrogenase levels were significantly higher in blood samples from the coronary perfusion catheter in the RIPC group. In a subsequent study in children, 4 cycles of 5-minute ischemia/ reperfusion in the lower limb before congenital heart surgery attenuated perioperative myocardial injury with lower postoperative troponin I and lower inotrope requirement at 3 and 6 hours after surgery. 10 A large number of smaller clinical trials have since been conducted to explore the utility of RIPC in the setting of cardiac surgery (Online Table I ), elective percutaneous coronary intervention, and primary percutaneous coronary intervention after acute MI. 11 Among the clinical scenarios that might benefit from RIPC, cardiac surgery has been investigated in the largest number of clinical trials. A review of the literature reveals that several smaller trials in adult and pediatric patients undergoing CABG, valve replacement, or surgery for congenital heart diseases reported improvement in cardiac enzyme release in patients who underwent RIPC protocols (Online Table I ). Importantly, RIPC failed to produce any significant improvement even in cardiac enzyme release in nearly half of these studies (Online Table I ). Thus, the overall evidence in support of cardioprotection afforded by RIPC was discordant at best. 11, 12 Another important point to consider is the nature and basis of evidence in support of protection by RIPC. In the vast majority of clinical trials that showed cardioprotection by RIPC during cardiac surgery, this conclusion was based on assessment of myocardial injury using the surrogate end points of peak or area under the curve of serial cardiac troponin assays 11 (Online Table I ). Although several trials did examine clinical parameters, including duration of mechanical ventilation, inotrope requirement, ICU stay, hospital stay, etc, RIPC was generally ineffective in improving these parameters (Online Table I ). Furthermore, even fewer trials examined short-and long-term clinical outcomes during follow-up; and only one 13 reported improvement with RIPC in hard clinical outcomes after 1 year of follow-up (Online Table I ). Therefore, and although cardiac enzyme release has been shown to correlate with outcomes, the evidence supporting the efficacy of RIPC in proof-of-concept clinical trials was indirect and remarkably weak.
No Suggestion of Improvement in Clinical Outcomes in Meta-Analyses
The discordant nature of the results from smaller trials of RIPC has resulted in repeated analyses of pooled data by several groups. In the first such effort, Takagi et al 14 (Online Table II ) analyzed data from only 4 RCTs and reported improvement in cardiac enzyme release after cardiac surgery in patients who underwent RIPC. More than 20 meta-analyses have since included trials that examined children and adults undergoing cardiac surgery (Online Table II) . A careful review of the results of these meta-analyses reveals that although RIPC was often associated with decreased cardiac enzyme release after cardiac surgery, these effects generally did not translate into improvements in patient outcomes. In fact, these enzymatic benefits did not even improve in-hospital clinical outcomes in most analyses. In contrast to results from meta-analyses that included cardiac surgery trials only, one meta-analysis that included patients undergoing percutaneous coronary intervention as well yielded more favorable effects with RIPC. 15 Interestingly, in a meta-analysis of RCTs that showed significantly reduced troponin levels with RIPC, this observation was most marked in trials that lacked full blinding. 16 The benefits lost significance in fully blinded trials, suggesting that lack of blinding was a significant confounding factor. 16 
Negative Results of Two Large RCTs
In a recent issue of The New England Journal of Medicine, two large multicenter phase III RCTs assessed the effects of RIPC on clinical end points after cardiac surgery. ERICCA enrolled 1612 high-risk patients (EuroSCORE 5 or higher) undergoing on-pump CABG (with or without valve surgery) at 30 centers across the United Kingdom.
1 Patients randomized to the RIPC group were subjected to 4 cycles of 5 minutes of ischemia and reperfusion of the upper arm after anesthesia and before surgical incision. RIPC did not significantly reduce the proportion of patients with a major cardiac or cerebral event, acute kidney injury within 72 hours, duration of hospital and ICU stays and area under the curve for troponin T. Patients who underwent RIPC walked a longer distance on the 6-minute walk test at 12 months, but only 360 of 1612 patients completed this test. Worryingly, RIPC showed a trend toward an increase in rate of death from cardiovascular causes, although the study was not sufficiently powered to detect this end point. RIPHeart enrolled 1403 patients undergoing elective cardiac surgery requiring cardiopulmonary bypass at 14 university hospitals in Germany. 2 Most patients underwent CABG alone, while others received mitral and aortic valve replacement/reconstruction or other surgeries, sometimes in combination. RIPHeart included lower risk (68.7% patients had a EuroSCORE of ≤5) and younger patients (mean age of patients in RIPHeart was ≈10 years less) compared with ERICCA. The RIPC protocol was similar to the one used in ERICCA. RIPC did not cause a significant reduction in the primary end point, which was a composite of death from any cause, nonfatal MI, new stroke, and acute renal failure. The RIPC arm showed a trend toward reduction of MI, although this did not reach significance. There was no significant difference in secondary end points: duration of ICU and hospital stay, duration of mechanical ventilation, levels of troponin T and I, creatinine level, new-onset atrial fibrillation, and incidence of postoperative delirium.
How Do We Reconcile These Results?
The results of these two large RCTs indicate that the strong promise from preclinical studies has failed to deliver measurable benefits in rigorous clinical trials. If we assume that RIPC indeed protects the heart in patients during cardiac surgery, its failure to do so in ERICCA and RIPHeart can be potentially attributable to several design issues. However, the validity of such an argument needs to be carefully judged in light of available evidence. First, the effects of various anesthetics on RIPC remain unclear. An earlier study reported that propofol inhibited RIPC by interfering with activation of the cardioprotective molecule STAT5. 17 However, when Hausenloy et al 18 used a targeted dose of propofol, RIPC was found to be cardioprotective. Kottenberg et al 19 further conducted a 4-arm trial, wherein patients undergoing CABG were randomized to receive isoflurane or propofol with or without RIPC. They reported that RIPC decreased
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Commentary on Remote Ischemic Preconditioningmyocardial damage during isoflurane administration but not propofol. On the other hand, Lucchinetti et al 20 used isoflurane for anesthesia and found RIPC to be ineffective for cardiac surgery. These results suggested that RIPC could not confer additional benefits above and beyond those already provided by isoflurane. 20 It is important to note that ERICCA had ≈90% of its patients on either volatile anesthetics or propofol, whereas the RIPHeart protocol used propofol. Importantly, in detailed subanalyses, ERICCA showed that anesthetics had no significant effect on primary and secondary outcomes. Furthermore, if the protective effects induced by standard anesthetic agents are strong enough to mask those of RIPC, RIPC may not be necessary after all.
Second, these large RCTs used RIPC protocols that were not standardized rigorously. However, as shown in Online Table I , the clinical trials performed thus far, including those showing significant reduction in enzyme release, have generally used 3 or 4 cycles of 5 minutes of ischemia interspersed with reperfusion. A thorough review of basic and preclinical data would also reveal that nearly all types of protocols have produced benefits in diverse experimental models and species. So, it seems unlikely that simple optimization of clinical RIPC protocol would have been sufficient to turn these negative results into positive effects. Third, the potential roles played by patients' comorbidities and medications cannot be discounted. However, patients enrolled in ERICCA and RIPHeart do represent patients likely to be subjected to RIPC in the real world, if its benefits are proven. Candidates for cardiac surgery often have multiple comorbidities and as a result, are on many different medications before and after surgery. If the benefits of RIPC are not evident in these populations that are likely to undergo cardiac surgery, the strength of its effects as well as its clinical use for cardiac surgery may both be questionable.
The final potential explanation for these negative findings is that RIPC simply does not work, at least during cardiac surgery. If we critically review the available evidence stemming from basic studies (which largely measured infarct size after experimentally induced MI), small proof-of-concept trials (which showed benefits mostly with regard to enzyme release, if at all), and meta-analyses of cardiac surgery trials alone (which did not suggest improvement in clinical outcomes), this possibility cannot be ignored.
Lessons Learned and Future Perspectives
The results of two well-conducted large RCTs, ERICCA, and RIPHeart, have caused a major setback to the potential applicability of RIPC for cardiac surgery. They have provided rather conclusive evidence that RIPC does not confer any important benefit to patients undergoing cardiac surgery. Although disappointing, this may not signify the end of the road for RIPC. RIPC may still be able to meaningfully protect the heart before elective percutaneous coronary intervention or acute MI-a concept that remains to be proven in large RCTs. However, the history of RIPC underscores the importance of scientific rigor and how critical it is for translating findings, however exciting, from the basic laboratories to therapies in patients. 21 Indeed, before proceeding to large RCTs, a concept needs to be tested carefully in clinically relevant disease models using the most rigorous methodologies; the proof-of-concept trials should assess relevant clinical outcomes rather than biochemical and surrogate markers; investigators should remain blinded whenever possible; data from smaller trials failing to support the popular belief should not be simply dismissed as exploratory, but rather utilized to improve future trial design; the value of hypotheses from meta-analyses should be tempered with critical evaluation of their heterogeneity and other methodologies; and finally, the RCTs need to be adequately powered to assess hard clinical end points. Failure to follow these methodological best practices underlies the failure to translate into clinical therapies not only RIPC but also many other putative cardioprotective interventions. 
